Arminder Jassar Selected Research

vadimezan

7/2007

The vascular disrupting agent, DMXAA, directly activates dendritic cells through a MyD88-independent mechanism and generates antitumor cytotoxic T lymphocytes.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Arminder Jassar Research Topics

Disease

2	Aortic Dissection 01/2020 - 02/2018
1	Stroke (Strokes) 01/2019
1	Neurologic Manifestations (Neurological Manifestations) 01/2019
1	Aneurysm (Aneurysms) 02/2018
1	Cardiomyopathies (Cardiomyopathy) 01/2014
1	Infarction (Infarctions) 01/2014
1	Necrosis 07/2007
1	Thymoma (Thymic Carcinoma) 07/2007
1	Neoplasms (Cancer) 07/2007

Drug/Important Bio-Agent (IBA)

1	Polypropylenes (Polypropylene)IBA 01/2014
1	OvalbuminIBA 07/2007
1	vadimezanIBA 07/2007
1	combretastatinIBA 07/2007
1	CytokinesIBA 07/2007
1	AntigensIBA 07/2007

Therapy/Procedure

2	Therapeutics 01/2020 - 01/2014
1	Thrombectomy 01/2019
1	Anesthesia 01/2019
1	Endovascular Aneurysm Repair 02/2018
1	Heart-Assist Devices 01/2014
1	Ligation 01/2014